Immuneering presents AACR data linking atebimetinib plus mGnP to longer survival in pancreatic cancer study

• Immuneering presented new exploratory clinical data at the 2026 AACR Conference on Pancreatic Cancer on atebimetinib with chemotherapy.
• Analyses linked maintaining body weight during treatment to longer survival versus weight loss, supporting a potential cachexia-related benefit.
• Survival appeared similar across moderate versus deeper tumor shrinkage, suggesting any measurable reduction may matter more than response depth.
• Findings reinforce the investment case for the ongoing Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer, which is enrolling patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834261) on September 28, 2026, and is solely responsible for the information contained therein.